Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

We Need More Research and Better Designs for Insulin Infusion Sets.

Heinemann L, Walsh J, Roberts R.

J Diabetes Sci Technol. 2014 Mar;8(2):199-202. Epub 2014 Feb 27. No abstract available.

2.
3.
4.

Who gains clinical benefit from using insulin pump therapy? A qualitative study of the perceptions and views of health professionals involved in the Relative Effectiveness of Pumps over MDI and Structured Education (REPOSE) trial.

Lawton J, Kirkham J, Rankin D, White DA, Elliott J, Jaap A, Smithson WH, Heller S; REPOSE Group.

Diabet Med. 2016 Feb;33(2):243-51. doi: 10.1111/dme.12879. Epub 2015 Sep 8.

PMID:
26248590
5.

Nonmetabolic complications of continuous subcutaneous insulin infusion: a patient survey.

Pickup JC, Yemane N, Brackenridge A, Pender S.

Diabetes Technol Ther. 2014 Mar;16(3):145-9. doi: 10.1089/dia.2013.0192. Epub 2013 Nov 1.

6.

Reduced Silent Occlusions with a Novel Catheter Infusion Set (BD FlowSmart): Results from Two Open-Label Comparative Studies.

Gibney M, Xue Z, Swinney M, Bialonczyk D, Hirsch L.

Diabetes Technol Ther. 2016 Mar;18(3):136-43. doi: 10.1089/dia.2015.0342. Epub 2015 Dec 24.

8.

Continuous subcutaneous insulin infusion therapy: A primer on insulin pumps.

Potti LG, Haines ST.

J Am Pharm Assoc (2003). 2009 Jan-Feb;49(1):e1-13; quiz e14-7. doi: 10.1331/JAphA.2009.08122. Review.

PMID:
19196588
9.

Unexplained hyperglycemia in continuous subcutaneous insulin infusion: evaluation and treatment.

Ponder SW, Skyler JS, Kruger DF, Matheson D, Brown BW.

Diabetes Educ. 2008 Mar-Apr;34(2):327-33. doi: 10.1177/0145721708315682.

PMID:
18375782
11.

Continuous subcutaneous insulin infusion (CSII) in inpatient setting: unmet needs and the proposal of a CSII unit.

Morviducci L, Di Flaviani A, Lauria A, Pitocco D, Pozzilli P, Suraci C, Frontoni S; CSII Study Group Of Lazio Region, Italy.

Diabetes Technol Ther. 2011 Oct;13(10):1071-4. doi: 10.1089/dia.2011.0056. Epub 2011 Jun 29.

PMID:
21714675
12.
14.

Successful treatment of young infants presenting neonatal diabetes mellitus with continuous subcutaneous insulin infusion before genetic diagnosis.

Rabbone I, Barbetti F, Marigliano M, Bonfanti R, Piccinno E, Ortolani F, Ignaccolo G, Maffeis C, Confetto S, Cerutti F, Zanfardino A, Iafusco D.

Acta Diabetol. 2016 Aug;53(4):559-65. doi: 10.1007/s00592-015-0828-7. Epub 2016 Feb 1.

PMID:
26831749
15.

Consensus evidence-based guidelines for use of insulin pump therapy in the management of diabetes as per Indian clinical practice.

Kesavadev J, Jain SM, Muruganathan A, Das AK; Diabetes Consensus Group.

J Assoc Physicians India. 2014 Jul;62(7 Suppl):34-41. Review.

PMID:
25668935
16.

Continuous subcutaneous insulin infusion (CSII) using an external insulin pump for the treatment of type 2 diabetes.

Reznik Y.

Diabetes Metab. 2010 Dec;36(6 Pt 1):415-21. doi: 10.1016/j.diabet.2010.08.002. Review.

PMID:
20888280
17.

Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes.

Colquitt JL, Green C, Sidhu MK, Hartwell D, Waugh N.

Health Technol Assess. 2004 Oct;8(43):iii, 1-171. Review.

18.

Analysis of the environmental impact of insulin infusion sets based on loss of resources with waste.

Pfützner A, Musholt PB, Malmgren-Hansen B, Nilsson NH, Forst T.

J Diabetes Sci Technol. 2011 Jul 1;5(4):843-7.

19.

Quality of life activities associated with adherence to insulin infusion pump therapy in the treatment of insulin dependent diabetes mellitus.

Wolf FM, Jacober SJ, Wolf LL, Cornell RG, Floyd JC Jr.

J Clin Epidemiol. 1989;42(12):1129-36.

PMID:
2585004
20.

Supplemental Content

Support Center